CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
Identifieur interne : 000388 ( PubMed/Corpus ); précédent : 000387; suivant : 000389CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
Auteurs : Awewura Kwara ; Margaret Lartey ; Kwamena W C. Sagoe ; Ernest Kenu ; Michael H. CourtSource :
- AIDS (London, England) [ 1473-5571 ] ; 2009.
English descriptors
- KwdEn :
- Adult, African Continental Ancestry Group (genetics), Aryl Hydrocarbon Hydroxylases (genetics), Benzoxazines (blood), Benzoxazines (pharmacokinetics), Cytochrome P-450 CYP2A6, Cytochrome P-450 CYP2B6, Dose-Response Relationship, Drug, Female, Genotype, Ghana, Glucuronosyltransferase (genetics), HIV Infections (blood), HIV Infections (drug therapy), HIV Infections (genetics), Humans, Male, Oxidoreductases, N-Demethylating (genetics), Polymorphism, Single Nucleotide, Predictive Value of Tests, Reverse Transcriptase Inhibitors (blood), Reverse Transcriptase Inhibitors (pharmacokinetics).
- MESH :
- chemical , blood : Benzoxazines, Reverse Transcriptase Inhibitors.
- chemical , genetics : Aryl Hydrocarbon Hydroxylases, Glucuronosyltransferase, Oxidoreductases, N-Demethylating.
- blood : HIV Infections.
- drug therapy : HIV Infections.
- genetics : African Continental Ancestry Group, HIV Infections.
- chemical , pharmacokinetics : Benzoxazines, Reverse Transcriptase Inhibitors.
- Adult, Cytochrome P-450 CYP2A6, Cytochrome P-450 CYP2B6, Dose-Response Relationship, Drug, Female, Genotype, Ghana, Humans, Male, Polymorphism, Single Nucleotide, Predictive Value of Tests.
Abstract
UDP-glucuronosyltransferase (UGT) 2B7 was recently identified as the main enzyme mediating efavirenz N-glucuronidation. In this study, we determined whether selected UGT2B7 polymorphisms could be used to enhance the prediction of efavirenz plasma concentrations from CYP2B6 and CYP2A6 genotypes.
DOI: 10.1097/QAD.0b013e3283319908
PubMed: 19779319
Links to Exploration step
pubmed:19779319Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.</title>
<author><name sortKey="Kwara, Awewura" sort="Kwara, Awewura" uniqKey="Kwara A" first="Awewura" last="Kwara">Awewura Kwara</name>
<affiliation><nlm:affiliation>Warren Alpert Medical School of Brown University, Rhode Island, USA. akwara@lifespan.org</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name>
</author>
<author><name sortKey="Sagoe, Kwamena W C" sort="Sagoe, Kwamena W C" uniqKey="Sagoe K" first="Kwamena W C" last="Sagoe">Kwamena W C. Sagoe</name>
</author>
<author><name sortKey="Kenu, Ernest" sort="Kenu, Ernest" uniqKey="Kenu E" first="Ernest" last="Kenu">Ernest Kenu</name>
</author>
<author><name sortKey="Court, Michael H" sort="Court, Michael H" uniqKey="Court M" first="Michael H" last="Court">Michael H. Court</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19779319</idno>
<idno type="pmid">19779319</idno>
<idno type="doi">10.1097/QAD.0b013e3283319908</idno>
<idno type="wicri:Area/PubMed/Corpus">000388</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000388</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.</title>
<author><name sortKey="Kwara, Awewura" sort="Kwara, Awewura" uniqKey="Kwara A" first="Awewura" last="Kwara">Awewura Kwara</name>
<affiliation><nlm:affiliation>Warren Alpert Medical School of Brown University, Rhode Island, USA. akwara@lifespan.org</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name>
</author>
<author><name sortKey="Sagoe, Kwamena W C" sort="Sagoe, Kwamena W C" uniqKey="Sagoe K" first="Kwamena W C" last="Sagoe">Kwamena W C. Sagoe</name>
</author>
<author><name sortKey="Kenu, Ernest" sort="Kenu, Ernest" uniqKey="Kenu E" first="Ernest" last="Kenu">Ernest Kenu</name>
</author>
<author><name sortKey="Court, Michael H" sort="Court, Michael H" uniqKey="Court M" first="Michael H" last="Court">Michael H. Court</name>
</author>
</analytic>
<series><title level="j">AIDS (London, England)</title>
<idno type="eISSN">1473-5571</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>African Continental Ancestry Group (genetics)</term>
<term>Aryl Hydrocarbon Hydroxylases (genetics)</term>
<term>Benzoxazines (blood)</term>
<term>Benzoxazines (pharmacokinetics)</term>
<term>Cytochrome P-450 CYP2A6</term>
<term>Cytochrome P-450 CYP2B6</term>
<term>Dose-Response Relationship, Drug</term>
<term>Female</term>
<term>Genotype</term>
<term>Ghana</term>
<term>Glucuronosyltransferase (genetics)</term>
<term>HIV Infections (blood)</term>
<term>HIV Infections (drug therapy)</term>
<term>HIV Infections (genetics)</term>
<term>Humans</term>
<term>Male</term>
<term>Oxidoreductases, N-Demethylating (genetics)</term>
<term>Polymorphism, Single Nucleotide</term>
<term>Predictive Value of Tests</term>
<term>Reverse Transcriptase Inhibitors (blood)</term>
<term>Reverse Transcriptase Inhibitors (pharmacokinetics)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Benzoxazines</term>
<term>Reverse Transcriptase Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Aryl Hydrocarbon Hydroxylases</term>
<term>Glucuronosyltransferase</term>
<term>Oxidoreductases, N-Demethylating</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>African Continental Ancestry Group</term>
<term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Benzoxazines</term>
<term>Reverse Transcriptase Inhibitors</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Cytochrome P-450 CYP2A6</term>
<term>Cytochrome P-450 CYP2B6</term>
<term>Dose-Response Relationship, Drug</term>
<term>Female</term>
<term>Genotype</term>
<term>Ghana</term>
<term>Humans</term>
<term>Male</term>
<term>Polymorphism, Single Nucleotide</term>
<term>Predictive Value of Tests</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">UDP-glucuronosyltransferase (UGT) 2B7 was recently identified as the main enzyme mediating efavirenz N-glucuronidation. In this study, we determined whether selected UGT2B7 polymorphisms could be used to enhance the prediction of efavirenz plasma concentrations from CYP2B6 and CYP2A6 genotypes.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19779319</PMID>
<DateCreated><Year>2009</Year>
<Month>10</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted><Year>2011</Year>
<Month>01</Month>
<Day>31</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>11</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5571</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>23</Volume>
<Issue>16</Issue>
<PubDate><Year>2009</Year>
<Month>Oct</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>AIDS (London, England)</Title>
<ISOAbbreviation>AIDS</ISOAbbreviation>
</Journal>
<ArticleTitle>CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.</ArticleTitle>
<Pagination><MedlinePgn>2101-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/QAD.0b013e3283319908</ELocationID>
<Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">UDP-glucuronosyltransferase (UGT) 2B7 was recently identified as the main enzyme mediating efavirenz N-glucuronidation. In this study, we determined whether selected UGT2B7 polymorphisms could be used to enhance the prediction of efavirenz plasma concentrations from CYP2B6 and CYP2A6 genotypes.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Mid-dose efavirenz plasma concentrations were determined in 94 HIV-infected Ghanaian patients at 2-8 weeks of antiretroviral therapy. CYP2B6 and CYP2A6 genotypes had been previously reported. UGT2B7 exon 2 single-nucleotide polymorphisms (SNPs) c.735A>G (UGT2B7*1c; rs28365062) and c.802C>T (H268Y; UGT2B7*2; rs7439366) were determined by direct sequencing with UGT2B7*1a defined as the reference allele. Relationships between efavirenz plasma concentrations, demographic variables and genotypes were evaluated by univariate and multivariate statistical approaches.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean (+/-SD) mid-dose efavirenz plasma concentration was 3218 (+/-3905) ng/ml with coefficient of variation of 121%. Independent predictors of efavirenz concentration included CYP2B6 c.516TT genotype (4030 ng/ml increase; 95% confidence interval 2882-5505 ng/ml, P < 0.001), UGT2B7*1a carrier status (475 ng/ml increase; 95% confidence interval 138-899 ng/ml, P = 0.004) and CYP2A6*9 and/or *17 carrier status (372 ng/ml increase; 95% confidence interval 74-742 ng/ml, P = 0.013). Overall, CYP2B6 c.516TT genotype, UGT2B7*1a carrier status and CYP2A6*9 or *17 carrier status accounted for 45.2, 10.1 and 8.6% of the total variance, respectively.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings demonstrate independent effects of CYP2A6 and UGT2B7 genetic variation on efavirenz disposition beyond that of the CYP2B6 polymorphisms. The development and testing of a pharmacogenetic algorithm for estimating the appropriate dose of efavirenz should incorporate genotypic data from both the oxidative and glucuronidation pathways.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kwara</LastName>
<ForeName>Awewura</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Warren Alpert Medical School of Brown University, Rhode Island, USA. akwara@lifespan.org</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lartey</LastName>
<ForeName>Margaret</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sagoe</LastName>
<ForeName>Kwamena W C</ForeName>
<Initials>KW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kenu</LastName>
<ForeName>Ernest</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Court</LastName>
<ForeName>Michael H</ForeName>
<Initials>MH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P30AI042853</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01GM061834</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>K23 AI071760</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 GM061834</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P30 AI042853</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>K23 AI071760-04</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P30 AI050410</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>AIDS</MedlineTA>
<NlmUniqueID>8710219</NlmUniqueID>
<ISSNLinking>0269-9370</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048588">Benzoxazines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018894">Reverse Transcriptase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber>
<NameOfSubstance UI="D001189">Aryl Hydrocarbon Hydroxylases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber>
<NameOfSubstance UI="C585710">CYP2A6 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber>
<NameOfSubstance UI="C585599">CYP2B6 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber>
<NameOfSubstance UI="D065637">Cytochrome P-450 CYP2A6</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber>
<NameOfSubstance UI="D065702">Cytochrome P-450 CYP2B6</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.5.-</RegistryNumber>
<NameOfSubstance UI="D010089">Oxidoreductases, N-Demethylating</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.4.1.-</RegistryNumber>
<NameOfSubstance UI="C491474">UGT2B7 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.4.1.17</RegistryNumber>
<NameOfSubstance UI="D014453">Glucuronosyltransferase</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>JE6H2O27P8</RegistryNumber>
<NameOfSubstance UI="C098320">efavirenz</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CitationSubset>X</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Drug Metab Dispos. 1999 Nov;27(11):1319-33</RefSource>
<PMID Version="1">10534318</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2001 Jan 5;15(1):71-5</RefSource>
<PMID Version="1">11192870</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharmacogenetics. 2001 Jul;11(5):399-415</RefSource>
<PMID Version="1">11470993</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Med Res. 2002 Jul 24;7(7):309-14</RefSource>
<PMID Version="1">12176680</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Pharmacol Ther. 2003 Jan;73(1):20-30</RefSource>
<PMID Version="1">12545140</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharmacogenomics J. 2003;3(1):17-26</RefSource>
<PMID Version="1">12629580</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pharmacol Exp Ther. 2003 Jul;306(1):287-300</RefSource>
<PMID Version="1">12676886</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Drug Metab Dispos. 2003 Sep;31(9):1125-33</RefSource>
<PMID Version="1">12920168</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ther Drug Monit. 2004 Jun;26(3):267-70</RefSource>
<PMID Version="1">15167626</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biochem Biophys Res Commun. 2004 Jul 9;319(4):1322-6</RefSource>
<PMID Version="1">15194512</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Drug Metab Dispos. 2004 Sep;32(9):1048-54</RefSource>
<PMID Version="1">15319348</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2004 Dec 3;18(18):2391-400</RefSource>
<PMID Version="1">15622315</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharmacogenet Genomics. 2005 Jan;15(1):1-5</RefSource>
<PMID Version="1">15864119</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>HIV Med. 2005 Jul;6 Suppl 2:62-83</RefSource>
<PMID Version="1">16011537</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS Res Hum Retroviruses. 2006 Mar;22(3):232-9</RefSource>
<PMID Version="1">16545009</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ther Drug Monit. 2006 Aug;28(4):517-25</RefSource>
<PMID Version="1">16885719</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Antimicrob Chemother. 2006 Dec;58(6):1299-302</RefSource>
<PMID Version="1">17032686</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Pharmacol Ther. 2007 Apr;81(4):557-66</RefSource>
<PMID Version="1">17235330</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr HIV Res. 2007 May;5(3):349-53</RefSource>
<PMID Version="1">17504177</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharmacogenomics. 2007 Jun;8(6):547-58</RefSource>
<PMID Version="1">17559344</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2007 Nov 1;45(9):1230-7</RefSource>
<PMID Version="1">17918089</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Annu Rev Pharmacol Toxicol. 2008;48:227-56</RefSource>
<PMID Version="1">17883329</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Clin Pharmacol. 2008 Apr;64(4):357-65</RefSource>
<PMID Version="1">18057928</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2008 Aug 6;300(5):555-70</RefSource>
<PMID Version="1">18677028</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Pharmacol. 2008 Sep;48(9):1032-40</RefSource>
<PMID Version="1">18728241</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Nov 30;22(18):2549-51</RefSource>
<PMID Version="1">19005282</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2009 Jan 28;23(3):433-4</RefSource>
<PMID Version="1">19188761</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2009 Mar;53(3):863-8</RefSource>
<PMID Version="1">19124658</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2009 Mar 27;23(6):742-4</RefSource>
<PMID Version="1">19279450</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharmacogenet Genomics. 2009 Apr;19(4):300-9</RefSource>
<PMID Version="1">19238117</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Clin Pharmacol. 2009 Apr;67(4):427-36</RefSource>
<PMID Version="1">19371316</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Pharmacol Ther. 2009 May;85(5):485-94</RefSource>
<PMID Version="1">19225447</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Drug Metab Dispos. 2009 Sep;37(9):1793-6</RefSource>
<PMID Version="1">19487252</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Pharmacol. 2009 Sep;49(9):1079-90</RefSource>
<PMID Version="1">19628728</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D044383" MajorTopicYN="N">African Continental Ancestry Group</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001189" MajorTopicYN="N">Aryl Hydrocarbon Hydroxylases</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D048588" MajorTopicYN="N">Benzoxazines</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065637" MajorTopicYN="N">Cytochrome P-450 CYP2A6</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065702" MajorTopicYN="N">Cytochrome P-450 CYP2B6</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N">Ghana</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014453" MajorTopicYN="N">Glucuronosyltransferase</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010089" MajorTopicYN="N">Oxidoreductases, N-Demethylating</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018894" MajorTopicYN="N">Reverse Transcriptase Inhibitors</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS202920</OtherID>
<OtherID Source="NLM">PMC2875867</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>9</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>9</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2011</Year>
<Month>2</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19779319</ArticleId>
<ArticleId IdType="doi">10.1097/QAD.0b013e3283319908</ArticleId>
<ArticleId IdType="pmc">PMC2875867</ArticleId>
<ArticleId IdType="mid">NIHMS202920</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000388 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000388 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= SidaGhanaV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:19779319 |texte= CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:19779319" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a SidaGhanaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |